Adjuvant Chemotherapy Is NOT Standard After Radical Prostatectomy
Chemotherapy is not routinely initiated after radical prostatectomy for localized prostate cancer. The established guidelines consistently recommend against adjuvant chemotherapy in this setting, as there is no proven survival benefit for patients with non-metastatic disease treated with surgery alone 1, 2.
What IS Recommended After Radical Prostatectomy
The evidence-based adjuvant options following radical prostatectomy are:
Adjuvant Radiotherapy (Not Chemotherapy)
- Timing: Within 1 year after surgery, once the patient has recovered 3
- Indications: Patients with adverse pathologic features including:
- Positive surgical margins (especially if diffuse: >10mm or ≥3 sites)
- Extracapsular extension
- Seminal vesicle invasion
- Persistently detectable PSA post-operatively
- Evidence: Immediate adjuvant RT is not routinely recommended but should be discussed with high-risk patients 2
Salvage Radiotherapy (Preferred Over Immediate Adjuvant RT)
- Timing: Early initiation when PSA rises (ideally PSA <0.5 ng/mL) 2
- Rationale: This approach allows monitoring and treats only those who demonstrate biochemical recurrence, avoiding overtreatment
Adjuvant Hormone Therapy
- Not recommended as routine adjuvant treatment after radical prostatectomy alone 1
- Exception: For node-positive disease (pN1), ADT is a category 1 option 3
When Chemotherapy IS Used in Prostate Cancer
Chemotherapy has specific, evidence-based roles, but none involve routine adjuvant use after prostatectomy:
Metastatic Hormone-Sensitive Disease
- ADT plus docetaxel is recommended as first-line treatment for metastatic, hormone-naïve disease in fit patients 2
- This is for patients with metastatic disease at diagnosis, not post-prostatectomy adjuvant therapy
Castration-Resistant Prostate Cancer (CRPC)
- Docetaxel is recommended for symptomatic metastatic CRPC 1, 2
- This represents disease progression, not adjuvant treatment
Investigational Settings Only
- Neoadjuvant docetaxel combined with RT and ADT for high-risk localized disease showed improved relapse-free survival in GETUG-12 4
- Critical distinction: This was for patients receiving radiotherapy, not radical prostatectomy
- These approaches remain investigational and are not standard practice 5, 6, 7
Common Pitfalls to Avoid
- Confusing adjuvant RT with adjuvant chemotherapy: The evidence supports adjuvant/salvage radiotherapy, not chemotherapy, after prostatectomy
- Misapplying metastatic disease protocols: ADT plus docetaxel is for metastatic disease, not localized disease treated with surgery
- Overtreatment: Even adjuvant RT is not routinely recommended; salvage RT based on PSA monitoring is often preferred to avoid unnecessary treatment 2
The Bottom Line
If your patient has undergone radical prostatectomy for localized prostate cancer, chemotherapy should not be started. Instead, monitor PSA levels closely and consider salvage radiotherapy if biochemical recurrence occurs. For patients with node-positive disease discovered at surgery, ADT (not chemotherapy) is the recommended systemic therapy 3. Chemotherapy is reserved for patients who develop metastatic disease or castration-resistant disease during follow-up, not as routine adjuvant treatment.